P84 Update on UK and Ireland’s pioneering pilot programme: liver transplantation for neuroendocrine tumour liver metastases

<h3>Introduction</h3> The incidence of neuroendocrine tumours (NETs) continues to rise. Liver metastases (LM) are commonly present at diagnosis. Liver transplantation (LT) has become an applicable treatment for a subset of these patients. A national multi-disciplinary panel has been created to help centres select patients based on the Milan criteria for liver transplantation in NETs. Here we report the progress of the pilot to date. <h3>Methods</h3> This is a retrospective review of patient data gathered from August 2021 to May 2024, extracted from the national MDT Meetings (nMDTM) database. This comprehensive database is managed and kept up-to-date by the nMDTM operations manager. Additional data was compiled from a multitude of sources, including referral proformas, Queen Elizabeth Hospital, Birmingham’s digital patient record and the Somerset Cancer <h3>Results</h3> From August 2021 through to April 2024, the nMDTM has offered consultations to 36 patients, who were felt to be appropriate for liver transplantation pathway (LTP). This consists of 18 males and 187 females, with range from 25 to 66. 28 nMDTM have taken place. 5 patients have undergone LT, 2 individual has been listed awaiting an offer and further 4 are currently undergoing assessment. There is a further 9 patients who are potentially appropriate pending further results. 5 individuals have opted out of the pathway. In total 11 centres have sent referrals through the nMDTM. <h3>Conclusion</h3> The nMDTM has successfully delivered the robust framework needed for the development and delivery of a national programme of LT in the highly challenging field of NETs. The nMDT panel have carried out activities to raise awareness amongst all stakeholders. This led to increasing participation by the relevant groups resulting in growth in numbers of patients requiring assessment. This prospective pilot functions as a case-controlled study that will provide robust evidence for the usefulness of liver transplantation in this setting. This programme opens avenues for future research. By leveraging a national database, blood and tissue banking, clinical trials and longitudinal cohort studies we can advance our understanding and improve outcomes for NET patients.